Pathophysiology of the presentation
The patient’s symptoms began
1 hour after an increased pyridostigmine dose. Pyridostigmine inhibits acetylcholinesterase, so more acetylcholine remains at nicotinic and muscarinic receptors. When the dose is too high, excessive cholinergic stimulation produces a
cholinergic crisis: muscarinic effects include
bronchorrhea, salivation, abdominal cramps, miosis, and bradycardia, while nicotinic effects produce muscle weakness. The gurgling respirations, pooled saliva, small pupils, heart rate of
52/min, and abdominal cramps fit this pattern. The respiratory rate of
30/min and SpO2 of
89% show that secretions are already compromising ventilation and oxygenation.
In cholinergic crisis, airway obstruction from excessive secretions is the immediate threat to life, not the bradycardia or cramps alone.
Why airway and breathing come first
The question asks for the
FIRST action. The airway-breathing-circulation (ABC) framework applies even when the underlying cause is pharmacologic. Secretions pooling in the mouth and gurgling respirations indicate that the upper airway is not protected. Suctioning clears the obstruction, and supplemental oxygen supports the falling SpO2.
No medication or diagnostic test can correct hypoxemia if the airway remains full of secretions. After airway and breathing are stabilized, the next steps are to hold the offending drug, notify the prescriber, give atropine as ordered, and obtain blood gases.
Distinguishing cholinergic crisis from myasthenic crisis
Both conditions cause weakness and respiratory failure, but the bedside clues differ. Myasthenic crisis results from too little acetylcholine effect, while cholinergic crisis results from too much. The table below compares the key features.
| Feature | Cholinergic crisis | Myasthenic crisis |
|---|
| Cause | Excess acetylcholinesterase inhibitor effect | Insufficient acetylcholine effect at the neuromuscular junction |
| Secretions | Increased, profuse, gurgling respirations | Usually not increased |
| Pupils | Small (miosis) | Normal or dilated |
| Heart rate | Bradycardia | Tachycardia |
| Gastrointestinal | Abdominal cramps, diarrhea | Not prominent |
| Muscle weakness | Present, with fasciculations | Present, without fasciculations |
Watch out! A patient with MG who becomes weaker after a dose increase should be assessed for cholinergic crisis. A common exam trap is to assume all weakness in MG is myasthenic crisis. The small pupils, bradycardia, and heavy secretions point the opposite direction.
Role of atropine and other interventions
Atropine is a muscarinic antagonist. It dries secretions and raises the heart rate, but it does not reverse nicotinic muscle weakness. In cholinergic crisis, atropine is given
after the airway is cleared and oxygenation is supported.
Atropine is an important treatment, but it is not the first action when secretions are actively obstructing the airway. Holding pyridostigmine prevents further cholinergic stimulation, and notifying the physician is essential, but both are secondary to immediate airway management. Arterial blood gas analysis confirms hypoxemia and hypercapnia, but pulse oximetry and clinical signs already indicate hypoxemia, so a blood gas draw should not delay suctioning and oxygen.
Clinical relevance from the evidence
Cholinergic crisis is rare but life-threatening because of excessive cholinergic stimulation
[1]. Pyridostigmine is primarily excreted by the kidneys, so standard doses can become excessive in renal impairment, but this patient has no reported renal dysfunction; the trigger here is the dose increase itself
[1]. Myasthenia gravis crisis is defined as an MG exacerbation requiring mechanical ventilation, and acute management begins with supportive care of the airway and breathing
[2]. Respiratory failure in MG can have unclear causes, so a rapid bedside assessment of secretions, pupils, heart rate, and bowel sounds helps differentiate the type of crisis before definitive treatment
[2][3].
References (research sources)
- [1]
Cholinergic Crisis Associated With Standard-Dose Pyridostigmine in a Hemodialysis Patient With Ocular Myasthenia Gravis and Marked Weight Loss.Research articleJunki K, Nozaki Y, Miyake K. (2026) · DOI: 10.7759/cureus.104810
- [2]
Myasthenia gravis crisis.Research articleBershad EM, Feen ES, Suarez JI (2008) · DOI: 10.1097/SMJ.0b013e31815d4398
- [3]
Sleep Disordered Breathing Mimicking Myasthenia Crisis in a Patient with Myasthenia Gravis.Research articleLai YC, Chen JY, Wu HD, Yang CC, Lin CH, Lee PL (2016) · DOI: 10.5664/jcsm.5816